ALK Positive Malignancies
1 clinical trials · Condition
◉ Watch ALK Positive Malignancies
| Record | Firm | Date |
|---|---|---|
| Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study (NCT02584933) | Novartis Pharmaceuticals | 2015-12-11 |
Track ALK Positive Malignancies automatically
Every clearance here is in the API, with alerts when new ones post.